SG10201803473WA - Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide - Google Patents
Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptideInfo
- Publication number
- SG10201803473WA SG10201803473WA SG10201803473WA SG10201803473WA SG10201803473WA SG 10201803473W A SG10201803473W A SG 10201803473WA SG 10201803473W A SG10201803473W A SG 10201803473WA SG 10201803473W A SG10201803473W A SG 10201803473WA SG 10201803473W A SG10201803473W A SG 10201803473WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- binding polypeptide
- immunosuppressive therapy
- alpha beta
- tcr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Abstract
METHODS FOR ENHANCING IMMUNOSUPPRESSIVE THERAPY BY MULTIPLE ADMINISTRATION OF ALPHA BETA TCR-BINDING POLYPEPTIDE 5 The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (αβ -TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-αβ -TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel 10 methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-αβTCR antibod ies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-αβTCR antibod ies and/or fragments thereof) to reduce T cells in the subject relative to γδ T cells in the subject are provided. 15 [No Figure]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361897809P | 2013-10-30 | 2013-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201803473WA true SG10201803473WA (en) | 2018-06-28 |
Family
ID=52021413
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201803473WA SG10201803473WA (en) | 2013-10-30 | 2014-10-30 | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
SG11201603193PA SG11201603193PA (en) | 2013-10-30 | 2014-10-30 | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603193PA SG11201603193PA (en) | 2013-10-30 | 2014-10-30 | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
Country Status (8)
Country | Link |
---|---|
US (2) | US11142575B2 (en) |
EP (1) | EP3063174B1 (en) |
CN (1) | CN106795220A (en) |
AU (2) | AU2014342182B2 (en) |
CA (1) | CA2928756A1 (en) |
MX (1) | MX2016005687A (en) |
SG (2) | SG10201803473WA (en) |
WO (1) | WO2015066379A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201803473WA (en) * | 2013-10-30 | 2018-06-28 | Genzyme Corp | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
US20180298099A1 (en) * | 2015-09-16 | 2018-10-18 | Harry C. Ledebur, Jr. | T-Cell Recepter (TCR) Targeting Therapies for Immune-Mediated Adverse Drug Reactions (ADRs) and Other Conditions |
CN108070644B (en) * | 2016-11-08 | 2021-06-29 | 国家卫生计生委科学技术研究所 | Diagnosis system for gestational hypertension |
EP3650539A4 (en) * | 2017-07-07 | 2021-08-18 | Hanmi Pharm. Co., Ltd. | Novel therapeutic enzyme fusion protein and use thereof |
CN109777778B (en) * | 2017-11-14 | 2023-07-18 | 中国科学院广州生物医药与健康研究院 | Genetically modified gamma delta T cells |
DE102017127984B4 (en) * | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Method for the propagation and activation of γδ T cells |
AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
MA55529A (en) * | 2019-04-03 | 2022-02-09 | Genzyme Corp | REDUCED FRAGMENTATION ANTI-ALPHA BETA TCR BINDING POLYPEPTIDES |
AU2020384369A1 (en) * | 2019-11-14 | 2022-05-26 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
AU2020416273A1 (en) * | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2018248A1 (en) * | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20050058641A1 (en) | 2002-05-22 | 2005-03-17 | Siemionow Maria Z. | Tolerance induction and maintenance in hematopoietic stem cell allografts |
EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
JP5597793B2 (en) | 2006-06-19 | 2014-10-01 | メルク・シャープ・アンド・ドーム・コーポレーション | ILT3-binding molecules and uses thereof |
DK2740744T3 (en) | 2007-01-09 | 2018-04-23 | Biogen Ma Inc | Sp35 antibodies and uses thereof |
AU2009288354A1 (en) | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
ME03447B (en) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
WO2012012737A2 (en) * | 2010-07-23 | 2012-01-26 | The University Of Toledo | Stable tregs and related materials and methods |
UY34317A (en) | 2011-09-12 | 2013-02-28 | Genzyme Corp | T cell antireceptor antibody (alpha) / ß |
SG10201803473WA (en) * | 2013-10-30 | 2018-06-28 | Genzyme Corp | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
-
2014
- 2014-10-30 SG SG10201803473WA patent/SG10201803473WA/en unknown
- 2014-10-30 AU AU2014342182A patent/AU2014342182B2/en not_active Ceased
- 2014-10-30 CN CN201480071641.4A patent/CN106795220A/en active Pending
- 2014-10-30 MX MX2016005687A patent/MX2016005687A/en unknown
- 2014-10-30 WO PCT/US2014/063254 patent/WO2015066379A2/en active Application Filing
- 2014-10-30 CA CA2928756A patent/CA2928756A1/en not_active Abandoned
- 2014-10-30 US US15/029,770 patent/US11142575B2/en active Active
- 2014-10-30 EP EP14810045.6A patent/EP3063174B1/en active Active
- 2014-10-30 SG SG11201603193PA patent/SG11201603193PA/en unknown
-
2020
- 2020-08-12 AU AU2020217395A patent/AU2020217395A1/en not_active Abandoned
-
2021
- 2021-09-08 US US17/469,179 patent/US20220098299A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015066379A3 (en) | 2015-07-09 |
MX2016005687A (en) | 2017-03-30 |
CA2928756A1 (en) | 2015-05-07 |
AU2014342182B2 (en) | 2020-05-14 |
US11142575B2 (en) | 2021-10-12 |
EP3063174A2 (en) | 2016-09-07 |
EP3063174B1 (en) | 2020-12-09 |
US20160244523A1 (en) | 2016-08-25 |
US20220098299A1 (en) | 2022-03-31 |
SG11201603193PA (en) | 2016-05-30 |
AU2020217395A1 (en) | 2020-09-03 |
WO2015066379A2 (en) | 2015-05-07 |
AU2014342182A1 (en) | 2016-05-19 |
CN106795220A (en) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201803473WA (en) | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide | |
MX2020011744A (en) | Improved dual specificity polypeptide molecule. | |
PH12020500368A1 (en) | B7-h4 antibodies and methods of use thereof | |
WO2014011988A3 (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
PH12017500918A1 (en) | Antibodies against cd73 and uses thereof | |
MY193013A (en) | Bispecific antibodies with tetravalency for a costimulatory tnf receptor | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
MX2020003046A (en) | Anti-hla-a2 antibodies and methods of using the same. | |
WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
NZ628314A (en) | Cd47 antibodies and methods of use thereof | |
AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
TR201910744T4 (en) | Monoclonal antibodies directed against growth and differentiation factor 15 (gdf-15). | |
MX2016015389A (en) | Antibodies binding to human and cynomolgus cd3 epsilon. | |
AU2018256498A1 (en) | Antibodies to amyloid beta | |
MX2015014017A (en) | Fc region variant. | |
WO2014011993A3 (en) | Epitope spreading associated with car t-cells | |
MX2015003150A (en) | Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereof. | |
UA117097C2 (en) | Antibodies to bradykinin b1 receptor ligands | |
BR112016020009A2 (en) | antibody, pharmaceutical composition, method for inhibiting cancer cell proliferation, hybridoma | |
TR201903312T4 (en) | Methods to reduce asthma exacerbation rates using benralizumab. | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
PL422231A1 (en) | Immunological CAR cells for treatment of tumours | |
WO2014016702A3 (en) | Humanized forms of monoclonal antibodies to human gnrh receptor | |
WO2014185908A3 (en) | Hybridoma clones, monoclonal antibodies, and methods of use | |
ZA202205383B (en) | Novel anti-nogo-a antibodies |